

CURRICULUM VITAE
The Johns Hopkins University School of Medicine

(Signature) _____
(Typed Name) James Robert Brašić, M.D., M.P.H.

December 20, 2017
(Date of this version)

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments (*in chronological order, earliest first by start date under each subcategory*)

Year-present University

- 1978 – 1979 Clinical Assistant Professor of Psychiatry, Boonshoft School of Medicine, Wright State University, Dayton, Ohio
- 1987 – 1988 Instructor in Psychiatry, Mount Sinai School of Medicine, New York, New York
- 1988 – 1991 Instructor in Psychiatry, New York University School of Medicine, New York, New York
- 1988 – 1995 Program Coordinator, Developmental Neurobiology Unit, New York University School of Medicine, New York, New York
- 1991-1998 Research Assistant Professor of Psychiatry, New York University School of Medicine, New York,
New York
- 1998-1999 Assistant Clinical Professor of Psychiatry, College of Physicians and Surgeons, Columbia University,
New York, New York
- 1998-2008 Adjunct Assistant Professor of Psychiatry, New York University School of Medicine, New York,
New York
- 2007-2009 Research Associate, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, The Johns Hopkins University, Baltimore, Maryland
- 2009-present Assistant Professor, Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, The Johns Hopkins University, Baltimore, Maryland

Year-present Hospital

- 1977 – 1979 Chief, Consultation-Liaison Psychiatry, Mental Health Department, United States Air Force Medical Center, Wright-Patterson Air Force Base, Ohio
- 1982 – 1983 Psychiatrist I, Rockland Children's Psychiatric Center, Orangeburg, New York
- 1983 – 1985 Assistant Attending Psychiatrist, Harlem Hospital Center, New York, New York
- 1985 – 1987 Associate Attending Psychiatrist, Harlem Hospital Center, New York, New York
- 1988 – 1995 Program Coordinator, Developmental Neurobiology Unit, Bellevue Hospital Center, New York, NY
- 1988 – 2009 Clinical Assistant Attending in Psychiatry, Bellevue Hospital Center, New York, NY
- 1998 - 1999 Assistant Attending Physician, Pediatric Psychiatric Clinic, Department of Psychiatry, New York-Presbyterian Hospital, New York New York
- 2008 - Active Staff Full Time in the Department of Radiology and Radiological Science-Division of Nuclear Medicine, The Johns Hopkins Hospital, Baltimore, Maryland
- 2014 - Courtesy Staff in the Department of Radiology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland

Year-present Other

- 1988 – 1994 Program Coordinator, Continuing Medical Education in Developmental Disabilities (C-MEDD), Institute for Basic Research in Developmental Disabilities, Office of Mental Retardation and Developmental Disabilities, Staten Island, NY
- 1995 Program Director, Continuing Medical Education in Developmental Disabilities (C-MEDD), Institute for Basic Research in Developmental Disabilities, Office of Mental Retardation and Developmental Disabilities, Staten Island, NY
- 1989-1995 Consultant Psychiatrist, Psychiatric Clinic, Manhattan Borough Developmental Services Office, New York, New York

Personal Data

Business Address: Johns Hopkins Outpatient Center
601 North Caroline Street, Room 3245
Baltimore MD 21287-0807

Telephone: (410) 955-8354

Fax: (410) 955-0696

E-mail: brasic@jhmi.edu

Education and Training *(in chronological order, earliest first by start date under each subcategory)*

Year Degree/Certificate, Discipline, Institution/City, Notes

Undergraduate

- 1972 A.B. cum laude, Medical Science, Boston University College of Arts and Sciences, Boston, MA
- 1989 -- 1992 Post-baccalaureate study, Mathematics, New York University College of Arts and Science, New York, NY

Doctoral/graduate

- 1972 M.D., Medicine, Boston University School of Medicine, Boston, MA
- 1980 A.M., Music, Washington University Graduate School of Arts and Sciences
- 1983 M.P.H., Sociomedical sciences, Joseph Mailman School of Public Health, Columbia University, New York, NY
- 1984 M.S., Biostatistics, Joseph Mailman School of Public Health, Columbia University, New York, NY
- 1987 M.A., Statistics, Graduate School of Arts and Sciences, Columbia University, New York, NY

Postdoctoral (Internship, residency, fellowship, etc.). Indicate primary mentors for scholarly activities where applicable

- 1972 -- 1973 Straight Medical Internship, University of Alabama Hospital, Birmingham, Alabama
- 1973 – 1975 Neurology Residency, Los Angeles County+University of Southern California Medical Center, Los Angeles, California
- 1975 – 1977 Psychiatry Residency, Barnes-Jewish Hospital, Saint Louis, Missouri
- 1980 – 1982 Child Psychiatry Residency, New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York, David Shaffer, MD, Mentor
- 1987 – 1988 Faculty Research Fellow in Clinical Developmental Neurobiology, Mount Sinai School of Medicine, New York, New York, J. Gerald Young, MD, Mentor
- 1988 – 1989 Faculty Research Fellow in Clinical Developmental Neurobiology, New York University School of Medicine, New York, New York, J. Gerald Young, MD, Mentor
- 1999 – 2007 Clinical and Research Postdoctoral Fellow, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Hospital, Baltimore, Maryland, Dean F. Wong, MD, PhD, Mentor

Professional Experience *(in chronological order, earliest first)*

Date	Position, Institution/City
1972 – 1973	Straight Medical Internship, University of Alabama at Birmingham Hospital, Birmingham, Alabama
1973 – 1975	Neurology Residency, Los Angeles County+University of Southern California Medical Center, Los Angeles, California
1975 – 1977	Psychiatry Residency, Barnes-Jewish Hospital, Saint Louis, Missouri
1977 – 1979	Chief, Consultation-Liaison Psychiatry, Mental Health Department, United States Air Force Medical Center, Wright-Patterson Air Force Base, Ohio
1978 – 1979	Clinical Assistant Professor of Psychiatry, Boonshoft School of Medicine, Wright State University, Dayton, Ohio
1980 – 1982	Child Psychiatry Residency, New York-Presbyterian Hospital/Columbia University Medical Center, New York, New York
1982 – 1983	Psychiatrist I, Rockland Children’s Psychiatric Center, Orangeburg, New York
1983 – 1985	Assistant Attending Psychiatrist, Harlem Hospital Center, New York, New York
1985 – 1987	Associate Attending Psychiatrist, Harlem Hospital Center, New York, New York
1987 – 1988	Faculty Research Fellow in Clinical Developmental Neurobiology and Instructor in Psychiatry, Mount Sinai School of Medicine, New York, New York
1988 – 2009	Clinical Assistant Attending in Psychiatry, Bellevue Hospital Center, New York, NY
1988 – 1989	Faculty Research Fellow in Clinical Developmental Neurobiology, New York University School of Medicine, New York, New York
1988 – 1991	Instructor in Psychiatry, New York University School of Medicine, New York, New York
1988 – 1995	Program Coordinator, Developmental Neurobiology Unit, Bellevue Hospital Center and the New York University School of Medicine, New York, NY
1991 -- 1998	Research Assistant Professor of Psychiatry, New York University School of Medicine, New York, New York
1998 -- 1999	Assistant Clinical Professor of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York
1998 -- 2008	Adjunct Assistant Professor of Psychiatry, New York University School of Medicine, New York, New York
1999 – 2007	Fellow, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, The Johns Hopkins University, Baltimore, Maryland
1999 – 2007	Clinical Fellow, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins Hospital, Baltimore, Maryland
2007 -- 2009	Research Associate, Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, The Johns Hopkins University, Baltimore, Maryland
2009 --	Assistant Professor, Division of Nuclear Medicine and Molecular Imaging, Russell H. Morgan Department of Radiology and Radiological Science, School of Medicine, The Johns Hopkins University, Baltimore, Maryland

PUBLICATIONS: *(in chronological order, earliest first, under each subcategory) Include only those published or in press; do **not** include submitted, in preparation, or planned.*

Please show all authors for all articles, chapters, etc.

*Please **bold your name** as an author in each reference*

Please indicate mentees by underlining their names

Please number all articles consecutively, starting from 1[one] under each subcategory

Please use standard reference citation format: Author F/MI, Second author F/MI, Third author F/MI, (etc.). Title. Journal. Year; Volume (Number): page-page. [Delete extra periods or commas between initials.]

Ex: 1. Jones BB, ***Smith JB**, Friend LM. Title of article. J Am Soc. 2015;14(1):16-42; *corresponding author; [SI/QI].

Please specify with a note after the publication your role(s) in clinical trial articles of 10 authors or more, if not first or senior author, such as data analysis, manuscript writing, obtaining funding, steering committee etc.

Please specify with a note after the publication joint authorship or corresponding authorship, if not obvious first or senior author

Please specify with [SI/QI] after the entry if the article can also be considered a system innovation/quality improvement publication

Original Research [OR] [including multi-authored clinical trials, experimental studies (including in vivo, in vitro, in silico studies), educational research, systematic reviews (e.g. Cochrane, IOM), meta-analyses]. Please indicate your role in multi-authored articles, if not first or senior author

1. Shaffer D, Gould MS, **Brasic J**, Ambrosini P, Fisher P, Bird H, Aluwahlia S. A children's global assessment scale (CGAS). Arch Gen Psychiatry. 1983;16(11):1228-1231.
Revised: Shaffer D, Gould MS, **Brasic J**, Ambrosini P, Fisher P, Bird H, Aluwahlia S. A children's global assessment scale (CGAS) (for children 4 to 16 years of age). Psychopharmacol Bull. 1985; 1(4):747-748.
 2. **Brasic JR**, Barnett JY, Kaplan D, Sheitman BB, Aisemberg P, Lafargue RT, Kowalik S, Clark A, Tsaltas MO, Young JG. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology. 1994;44(7):1309-1312.
 3. **Brasic JR**, Barnett JY. Hyperkinesias in a prepubertal boy with autistic disorder treated with haloperidol and valproic acid. Psychol Rep. 1997;80(1):163-170.
 4. **Brasic JR**, Barnett JY, Ahn SC, Nadrich RH, Will MV, Clair A. Clinical assessment of self-injurious behavior. Psychol Rep. 1997;80(1):155-160.
 5. **Brasic JR**, Barnett JY, Aisemberg P, Ahn SC, Nadrich RH, Kaplan D, Ahmad R, Mendonça MF. Dyskinesias subside off all medication in a boy with autistic disorder and severe mental retardation. Psychol Rep. 1997;81(3):755-767.
 6. **Brasic JR**, Young JG, Furman J, Conte RM, Baisley WE, Jaslow RI. Psychoactive Medication Quality Assurance Rating Survey (PQRS). J Dev Phys Disabil. 1997;9(4):311-336.
 7. **Brasic JR**, Barnett JY, Sheitman BB, Lafargue RT, Ahn SC. Clinical assessment of adventitious movements. Psychol Rep. 1998;83(3 Part 1):739-750.
 8. **Brasic JR**, Barnett JY, Sheitman BB, Lafargue RT, Kowalik S, Kaplan D, Tsaltas MO, Ahmad R, Nadrich RH, Mendonça MF. Behavioral effects of clomipramine on prepubertal boys with autistic disorder and severe mental retardation. CNS Spectr. 1998;3(10):39-46.
 9. **Brasic JR**, Will MV, Ahn SC, Nadrich RH, McNally G. A review of the literature and a preliminary study of family compliance in a developmental disabilities clinic. Psychol Rep. 1998;82(1):275-286.
 10. **Brasic JR**, Zagzag D, Kowalik S, Prichep L, John ER, Liang HG, Klutchko B, Cancro R, Sheitman BB, Buchsbaum M, Brathwaite C. Progressive catatonia. Psychol Rep. 1999;84(1):239-246.
 11. **Brašić JR**, Barnett JY, Will MV, Nadrich RH, Sheitman BB, Ahmad R, Mendonça MF, Kaplan D, Brathwaite C. Dyskinesias differentiate autistic disorder from catatonia. CNS Spectr. 2000;5(12):19-22.
 12. **Brašić JR**, Furman J, Conte RM, Baisley WE, Jaslow RI. Assuring the quality of the utilization of psychoactive medication by people with mental retardation and developmental disabilities by assessing dosages. German Journal of Psychiatry. 2000;3(3):7-12; <http://www.gjpsy.uni-goettingen.de/gjp-article-brasic2.htm>
 13. **Brašić JR**, Zagzag D, Kowalik S, Prichep L, John ER, Barnett JY, Bronson B, Nadrich RH, Cancro R, Buchsbaum M, Brathwaite C. Clinical manifestations of progressive catatonia. German Journal of Psychiatry. 2000;3(2):13-24. <http://www.gwdg.de/~bbandel/gjp-article-brasic.htm>
- Revised:** Brasic JR. A 20-year-old man who stopped speaking. Medscape. Updated July 31, 2017.
Available at: http://reference.medscape.com/viewarticle/883207_6 Accessed on August 8, 2017.
14. **Brašić JR**, Barnett JY, Zelfhof R, Tarpley H. Dopamine antagonists ameliorate the dyskinesias, aggression, and inattention of persons with mental retardation referred to psychiatric clinics. German

- Journal of Psychiatry. 2001;4(1):9-16; <http://www.gipsy.uni-goettingen.de/gjp-article-brasic3.pdf>
15. Zhou Y, **Brašić JR**, Musachio JL, Zukin SR, Kuwabara H, Crabb AH, Endres CJ, Hilton J, Fan H, 123
Wong DF. Human [¹¹C]5-I-A-85380 dynamic SPECT studies in normals: kinetic analysis and parametric imaging. IEEE Nucl Sci Symp Conf Rec. 2001;3:1335-1340.
16. **Brašić JR**. A creative senior citizen with likely bipolar II disorder and likely histrionic personality disorder expresses herself. German Journal of Psychiatry. 2002;5(1):5-23; <http://www.gipsy.uni-goettingen.de/gjp-article-brasic4-text.pdf> and <http://www.gipsy.uni-goettingen.de/gjp-article-brasic4-figures.pdf>
17. **Brašić JR**. Conversion disorder in childhood. German Journal of Psychiatry. 2002;5(2):54-61; <http://www.gipsy.uni-goettingen.de/gjp-article-brasic-conversion.pdf>
18. **Brašić JR**, Kisnad HV, Leven LI, Nettleton JW, Arzola JL, Zhou Y. Quality assurance of the community placement of institutional residents. German Journal of Psychiatry. 2002;5(4):95-114; <http://www.gipsy.uni-goettingen.de/gjp-article-brasic-quality.pdf>
19. Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, **Brašić JR**, Zhou Y, Grace AA, Wong DF. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry. 2002;159(8):1329-1336.
20. **Brašić JR**, Furman JW, Conte RM, Baisley WE, Jaslow RI. Assessing the quality of the administration of psychoactive medication. J Dev Phys Disabil. 2003;15(3):185-205.
21. **Brašić JR**, Furman JW, Conte RM, Baisley WE, Jaslow RI. Psychoactive Medication Quality Assurance Rating Survey (PQRS) Screening Criteria. J Dev Phys Disabil. 2003;15(3):231-254.
22. Zhou Y, Endres CJ, **Brašić JR**, Huang S-C, Wong DF. Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model. NeuroImage. 2003;18(4):975-989.
23. **Brašić JR**, Barnett JY, Kowalik S, Tsaltas MO, Ahmad R. Neurobehavioral assessment of children and adolescents attending a developmental disabilities clinic. *Psychol Rep*. 2004;95(3):1079-1086.
24. Alexander M, Rothman RB, Baumann MH, Endres CJ, **Brašić JR**, Wong DF. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon *Papio anubis*. Synapse. 2005;56(2):94-99.
25. Oswald LM, Wong DF, McCaul M, Zhou Y, Kuwabara H, Choi L, **Brašić J**, Wand GS. Relationships among ventral striatal dopamine release, cortisol secretion, and subjective responses to amphetamine. Neuropsychopharmacology. 2005;30(4):821-832.
26. **Brašić JR**, Holland JA. Reliable classification of case-control studies of autistic disorder and obstetric complications. J Dev Phys Disabil. 2006;18(4):355-381.
27. Mintzer MZ, Kuwabara H, Alexander M, **Brašić JR**, Ye W, Ernst M, Griffiths RR, Wong DF. Dose effects of triazolam on brain activity during episodic memory encoding: a PET study. Psychopharmacology. 2006;188:445-461.
28. Munro CA, McCaul ME, Oswald LM, Wong DF, Zhou Y, **Brašić J**, Kuwabara H, Kumar A, Alexander M, Ye W, Wand GS. Striatal dopamine release and family history of alcoholism. Alcohol Clin Exp Res. 2006;30(7):1143-1151.
29. Munro CA, McCaul ME, Wong DF, Oswald LM, Zhou Y, **Brašić J**, Kuwabara H, Kumar A, Alexander M, Ye W, Wand GS. Sex differences in striatal dopamine release in healthy adults. Biol Psychiatry. 2006;59(10):966-974.
30. Wong DF, Kuwabara H, Schretlen DJ, Bonson KR, Zhou Y, Nandi A, **Brašić JR**, Kimes AS, Maris MA, Kumar A, Contoreggi C, Links J, Ernst M, Rousset O, Zukin S, Grace AA, Lee JS, Rohde C, Jasinski DR, Gjedde A, London ED. Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving. Neuropsychopharmacology. 2006;31:2716-2727; erratum in: Neuropsychopharmacology. 2007;32:256.
31. Zhou Y, Chen MK, Endres CJ, Ye W, **Brašić JR**, Alexander M, Crabb AH, Guilarte TR, Wong DF. An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. NeuroImage. 2006;33(2):550-563.

32. **Brašić JR**, Holland JA. A qualitative and quantitative review of obstetric complications and autistic disorder. *J Dev Phys Disabil*. 2007;19(4):337-364.
33. Oswald LM, Wong DF, Zhou Y, Kumar A, **Brasic JR**, Alexander M, Ye W, Kuwabara H, Hilton J, Wand GS. Impulsivity and chronic stress are associated with amphetamine-induced striatal dopamine release. *NeuroImage*. 2007;36:153-166.
34. Chen MK, Kuwabara H, Zhou Y, Adams RI, **Brašić JR**, McGlothan JL, Verina T, Burton NC, Alexander M, Kumar A, Wong DF, Guilarte TR. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. *J Neurochem*. 2008;105:78-90.
35. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, **Brasic J**, Ye W, Alexander M, Dannals RF, Wong DF, Ricaurte GA. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. *Synapse*. 2008;62:91-100.
36. Wong DF, **Brašić JR**, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, Nandi A, Maris MA, Alexander M, Ye W, Rousset O, Kumar A, Szabo Z, Gjedde A, Grace AA. Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette Syndrome: clues from an *in vivo* neurochemistry study with PET. *Neuropsychopharmacology*. 2008;33:1239-1251.
37. **Brašić JR**, Zhou Y, Musachio JL, Hilton J, Fan H, Crabb A, Endres CJ, Reinhardt MJ, Dogan AS, Alexander M, Rousset O, Maris MA, Galecki J, Nandi A, Wong DF. Single photon emission computed tomography experience with (S)-5-[¹²³I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers. *Synapse*. 2009;63(4):339-358.
38. Feás Sánchez X, **Brasic JR**, Fente Sampayo CA, Cepeda Sáez A. La quinina y sus posibles implicaciones toxicológicas: análisis de aguas tónicas en España [Quinine potential toxicological implications: analysis of tonic waters in Spain]. *Revista Española de Nutrición Comunitaria [Spanish Journal of Community Nutrition]*. 2009;15(3):97-102.
39. Zhou Y, Ye W, **Brasic JR**, Crabb AH, Hilton J, Wong DF. A consistent and efficient graphical analysis method to improve the quantification of reversible tracer binding in radioligand receptor dynamic PET studies. *NeuroImage*. 2009;44(3):661-670.
40. Steele KE, Prokopowicz GP, Schweitzer MA, Magunson TH, Lidor AO, Kuwabara H, Kumar A, **Brasic J**, Wong DF. Alterations of central dopamine receptors before and after gastric bypass surgery. *Obes Surg*. 2010;20(3):369-374.
41. Wong DF, Kuwabara H, Horti AG, Raymond V, **Brasic J**, Guevara M, Ye W, Dannals RF, Ravert HT, Nandi A, Rahmim A, Ming JE, Grachev I, Roy C, Cascella N. Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [(11)C]OMAR. *NeuroImage*. 2010;52(4):1505-1513.
42. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymond V, Ravert HT, Dannals RF, Nandi A, **Brasic JR**, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). *J Nucl Med*. 2010;51(6):913-920; erratum in: *J Nucl Med*. 2010;51(8):1327.
43. Zhou Y, Ye W, **Brašić JR**, Wong DF. Multi-graphical analysis of dynamic PET. *NeuroImage*. 2010;49:2947-2957.
44. Earley CJ, Kuwabara H, Wong DF, Gamaldo C, Salas R, **Brasic J**, Ravert HT, Dannals RF, Allen RP. The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. *Sleep*. 2011;34(3):341-347.
45. **Brašić JR**, Bibat G, Kumar A, Zhou Y, Hilton J, Yablonski ME, Dogan AS, Guevara MR, Stephane M, Johnston M, Wong DF, Naidu S. Correlation of the vesicular acetylcholine transporter densities in the striata to the clinical abilities of women with Rett syndrome. *Synapse*. 2012;66:471-482.
46. **Brašić JR**, Cascella N, Kumar A, Zhou Y, Hilton J, Raymond V, Crabb A, Guevara MR, Horti AG, Wong DF. Positron emission tomography (PET) experience with 2-[¹⁸F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[¹⁸F]FA) in the living human brain of smokers with paranoid schizophrenia. *Synapse*. 2012;66:352-368.
47. Gui J-C, **Brašić JR**, Liu X-D, Gong G-Y, Zhang G-M, Liu C-J, Gao G-Q. Bone mineral density in

- postmenopausal Chinese women treated with calcium fortification in soymilk and cow's milk. *Osteoporos Int.* 2012;23(5):1563-1570.
48. Liu C, **Brašić JR**, Liu X, Li H, Xiang X, Luo Z, Wang Y, Kuai D, Zhang G, Zaknun JJ. Timing and optimized acquisition parameters for the whole-body imaging of ¹⁷⁷Lu-EDTMP toward performing bone pain palliation treatment. *Nucl Med Commun.* 2012;33(1):90-96.
 49. Earley CJ, Kuwabara H, Wong DF, Gamaldo C, Salas RE, **Brašić JR**, Ravert HT, Dannals RF, Allen RP. Increased synaptic dopamine in the putamen in restless legs syndrome. *Sleep.* 2013;36:51-57.
 50. Martin-Facklam M, Pizzagalli F, Zhou Y, Ostrowitzki S, Raymont V, **Brašić JR**, Parkar N, Umbricht D, Dannals RF, Goldwater R, Wong DF. Glycine transporter type 1 occupancy by bitopertin: a positron emission tomography study in healthy volunteers. *Neuropsychopharmacology.* 2013;38:504-512.
 51. Rosenberg PB, Wong DF, Edell SL, Ross JS, Joshi AD, **Brašić JR**, Zhou Y, Raymont V, Kumar A, Ravert HT, Dannals RF, Pontecorvo MJ, Skovronsky DM, Lyketsos CG. Cognition and amyloid load in Alzheimer Disease imaged with florbetapir F 18 (AV-45) positron emission tomography. *Am J Geriatr Psychiatry.* 2013;21:272-278.
 52. Wong DF, Kuwabara H, **Brašić JR**, Stock T, Maini A, Gean EG, Loebel A. Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. *Psychopharmacology.* 2013;229:245-252.
 53. Wong DF, Kuwabara H, Kim J, **Brašić JR**, Chamroonrat W, Gao Y, Valentine H, Willis W, Mathur A, McCaul ME, Wand G, Gean EG, Dannals RF, Horti AG. PET imaging of high-affinity $\alpha 4\beta 2$ nicotinic acetylcholine receptors in humans with ¹⁸F-AZAN, a radioligand with optimal brain kinetics. *J Nucl Med.* 2013;54:1308-1314.
 54. Wong DF, Moghekar AR, Rigamonti D, **Brašić JR**, Rousset O, Willis W, Buckley C, Smith A, Gok B, Sherwin P, Grachev ID. An *in vivo* evaluation of cerebral cortical amyloid with [¹⁸F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients. *Mol Imaging Biol.* 2013;15(2):230-237.
 55. Wong DF, Ostrowitzki S, Zhou Y, Raymont V, Hofmann C, Borroni E, Kumar A, Parkar N, **Brašić JR**, Hilton J, Dannals RF, Martin-Facklam M. Characterization of [¹¹C]RO5013853, a novel PET tracer for the glycine transporter type 1 (GlyT1) in humans. *NeuroImage.* 2013;75:282-290.
 56. Wong DF, Waterhouse R, Kuwabara H, Kim J, **Brašić JR**, Chamroonrat W, Stabins M, Holt DP, Dannals RF, Hamill TG, Mozley PD. ¹⁸F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry. *J Nucl Med.* 2013;54:388-396.
 57. Yuan J, Lv R, **Brašić JR**, Han M, Liu X, Wang Y, Zhang G, Liu C, Li Y, Deng Y. Dopamine transporter dysfunction in Han Chinese people with chronic methamphetamine dependence after a short-term abstinence. *Psychiatry Res.* 2014;221:92-96.
 58. Oswald LM, Wand GS, Kuwabara H, Wong DF, Zhu S, **Brasic JR**. History of childhood adversity is positively associated with ventral striatal dopamine responses to amphetamine. *Psychopharmacology (Berl).* 2014;231(12):2417-2433.
 59. Wong D, Ostrowitzki S, Zhou Y, Alberati D, Pinard E, Raymont V, Martin-Facklam M, Hofmann C, Parkar N, **Brasic J**, Hilton J, Dannals R, Borroni E. [¹¹C]-RO5013853: a new PET radioligand for the glycine transporter type 1. *Neuropsychopharmacology*; 2014;39(9):2272 [corrigendum].
 60. Wong DF, Kuwabara H, Pomper M, Holt DP, **Brasic JR**, George N, Frolov B, Willis W, Gao Y, Valentine H, Nandi A, Gapasin L, Dannals RF, Horti AG. Human brain imaging of $\alpha 7$ nAChR with [¹⁸F]ASEM: a new PET radiotracer for neuropsychiatry and determination of drug occupancy. *Mol Imaging Biol.* 2014;16(5):730-738.
 61. Kuwabara H, Heshman SJ, **Brasic JR**, Contoreggi C, Cascella N, Mackowick KM, Taylor R, Rousset O, Willis W, Huestis MA, Concheiro M, Wand G, Wong DF, Volkow ND. Mu opioid receptor binding correlates with nicotine dependence and reward in smokers. *PLoS One.* 9(12): e113694. doi:10.1371/journal.pone.0113694 eCollection 2014.
 62. Spira AP, Yager C, Brandt J, Smith GS, Zhou Y, Mathur A, Kumar A, **Brašić JR**, Wong DF, Wu MN. Objectively measured sleep and β -amyloid burden in older adults: A pilot study. *SAGE Open Med.* 2014

DOI: 10.1177/2050312114546520.

63. Davis RE, Vanover KE, Zhou Y, **Brašić JR**, Guevara M, Bisuna B, Ye W, Raymont V, Willis W, Kumar A, Gapasin L, Goldwater DR, Mates S, Wong DF. ITI-007 demonstrates brain occupancy at serotonin 5-HT_{2A} and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers. *Psychopharmacology (Berl)*. 2015;232(15):2863-2872.
64. Kim J, Horti AG, Mathews WB, Pogorelov V, Valentine H, **Brasic JR**, Holt DP, Ravert HT, Dannals RF, Zhou L, Jedynak B, Kamiya A, Pletnikov MV, Wong DF. Quantitative multi-modal brain autoradiography of glutamatergic, dopaminergic, cannabinoid, and nicotinic receptors in mutant Disrupted-In-Schizophrenia-1 (DISC1) mice. *Mol Imaging Biol*. 2015;17:355-363.
65. Oswald LM, Wand GS, Wong DF, Brown CH, Kuwabara H, **Brašić JR**. Risky decision-making and ventral striatal dopamine responses to amphetamine: a positron emission tomography [¹¹C]raclopride study in healthy adults. *NeuroImage*. 2015;113:26-36.
66. Schneider JS, Cambi F, Gollomp SM, Kuwabara H, **Brašić JR**, Leiby B, Sendek S, Wong DF. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding. *J Neurol Sci*. 2015;356(1-2):118-123.
67. Anderson BA, Kuwabara H, Wong DF, Gean EG, Rahmim A, **Brašić JR**, George N, Frolov B, Courtney SM, Yantis S. The role of dopamine in value-based attentional orienting. *Curr Biol*. 2016;26(4):550-555.
68. Anderson BA, Kuwabara H, Wong DF, Roberts J, Rahmim A, **Brašić JR**, Courtney SM. Linking dopaminergic reward signals to the development of attentional bias: a positron emission tomographic study. *NeuroImage*. 2017; 157: 27-33.

Review Articles [RA]

1. **Brasic JR**. Hysteria: diagnosis and treatment. In: Levy RA (Editor). *Proceedings of the twenty-fifth annual conference of air force behavioral scientists* United States Air Force School of Aerospace Medicine, Aerospace Medical Division (AFSC), Brooke Air Force Base, Texas. 1978;8-16.
2. **Brasic JR**. The emergency evaluation of organic brain syndrome. In: Levy RA (Editor). *Proceedings of the twenty-sixth annual conference of air force behavioral scientists* United States Air Force School of Aerospace Medicine, Aerospace Medical Division (AFSC), Brooke Air Force Base, Texas. 1979;148-158.
3. **Brasic JR**. Hallucinations. *Percept Mot Skills*. 1998;86(3):851-877.
4. **Brasic JR**. Pets and health. *Psychol Rep*. 1998;83(3):1011-1024.
5. **Brasic JR**. Movements in autistic disorder. *Med Hypotheses*. 1999;53(1):48-49.
6. **Brasic JR**. Should people with nocturnal leg cramps drink tonic water and bitter lemon? *Psychol Rep*, 1999;84(2) 355-367.
7. **Brasic JR**, Fogelman D. Clinician safety. *Psychiatr Clin North Am*. 1999;23(4):923-940.
8. **Brasic JR**, Furman JW, Conte RM, Baisley WE. Continuous quality improvement in child and adolescent psychopharmacology. *Child Adolesc Psychopharmacol News*. 1999;4(3):9-10.
9. **Brasic JR**. Differentiating myoclonus from tics. *Psychol Rep*. 2000;86(1):155-156.
10. **Brasic JR**, Gianutsos JG. Neuromotor assessment and autistic disorder. *Autism: The International Journal of Research and Practice*. 2000;4(3):287-298.
11. Lafargue T, **Brasic J**. Neurodevelopmental hypothesis of schizophrenia: a central sensory disturbance. *Med Hypotheses*. 2000;55(4):314-318.
12. **Brašić JR**. Clinical assessment of tics. *Psychol Rep*. 2001;89(1):48-50.
13. **Brasic JR**, Nadrich RH, Kleinrock S, Brathwaite C. Do families comply with child and adolescent psychopharmacology? *Child Adolesc Psychopharmacol News*. 2001;6(2):6,7,10.
14. Wong DF, **Brašić JR**. In vivo imaging of neurotransmitter systems in neuropsychiatry. *Clin Neurosci Res*. 2001;1(1-2):35-45.
15. **Brašić JR**. Beneficial and adverse effects of pets. *Psychol Rep*. 2002;91(2):444.
16. **Brašić JR**. Documentation of demographic data. *Psychol Rep*. 2003;9 (1):151-152.
17. **Brašić JR**. Obtaining funding for new researchers in psychology. *Psychol Rep*. 2003;93(1):276-278
18. **Brašić JR**. Risks of the consumption of beverages containing quinine. *Psychol Rep*. 2003;93(3):1022-1024

19. Wong DF, Maini A, Rousset OG, **Brašić JR**. Positron emission tomography--a tool for identifying the effects of alcohol dependence on the brain. *Alcohol Res Health*. 2003;27(2):161-173.
20. **Brašić JR**. Documentation of ethnicity. *Psychol Rep*. 2004;95(3):859-861.
21. Wong DF, **Brašić JR**. Progress in the neuropsychiatry of schizophrenia. *Psychiatr Times*. 2005;22(3):57,58,60.
22. **Brašić JR**. Screening people with disturbed sleep for depression. *Perceptual and Motor Skills* 2006; 103: 765-766
23. **Brašić JR**. Does stimulant medication decrease the lower extremity response times of children with and without Attention-Deficit/Hyperactivity Disorder. *Percept Mot Skills*. 2007;104:67-68.
24. **Brašić JR**. Monitoring people treated with isotretinoin for depression. *Psychol Rep*. 2007;100:1312-1314.
25. Wong DF, Gründer G, **Brašić JR**. Brain imaging research: does the science serve clinical practice? *Int Rev Psychiatry*. 2007;19(5):541-558.
26. Liu X, **Brašić JR**, Zhou Y. Differentiation of non-pharmacological from pharmacological dopamine release in the living human brain. *Curr Med Imaging Rev*. 2011;7(2):104-106.
27. **Brašić JR**. Neurotransmitter visualization in schizophrenia. *J Biomed Graph Comput*. 2013;3(2):30-45.
28. **Brasic JR**. Asperger Syndrome. Medscape Reference. Updated March 26, 2014. Available at: <http://emedicine.medscape.com/article/912296-overview>
29. **Brasic JR**. Autism. Medscape Drugs & Diseases. Updated April 21, 2017. Available at: <http://emedicine.medscape.com/article/912781-overview>
30. **Brasic JR**. Pediatric Obsessive-Compulsive Disorder. Medscape Reference. Updated November 9, 2015. Available at: <http://emedicine.medscape.com/article/1826591-overview>
31. **Brasic JR**. PET Scanning in Autism Spectrum Disorders. Medscape Reference. Updated October 14, 2015. Available at: <http://emedicine.medscape.com/article/1155568-overview>
32. George N, Gean EG, Nandi A, Frolov B, Zaidi E, Lee H, **Brašić JR**, Wong DF. Advances in CNS imaging agents: focus on PET and SPECT tracers in experimental and clinical use. *CNS Drugs*. 2015;29:313-330.
33. **Brasic JR**. Catatonia. Medscape Reference. Updated November 3, 2016. Available at: <http://emedicine.medscape.com/article/1154851-overview>
34. **Brasic JR**. Tardive Dyskinesia. Medscape Reference. Updated April 24, 2017. Available at: <http://emedicine.medscape.com/article/1151826-overview>
35. Royeen CB, **Brašić JR**, Dvorak L, Provoziak-O'Brien C, Sethi C, Seyed SO. Neuroscience Literacy: "Brain Tells" as signals of brain dysfunction affecting daily life. *J Allied Health*. 2016; 45: 278-282.
36. Hwang BJ, Mohamed MA, **Brašić JR**. Molecular imaging of autism spectrum disorder. *International Review of Psychiatry*. 2017; 29 (6): 530-554. <http://dx.doi.org/10.1080/09540261.2017.1397606>

Case Reports [CR]

1. Alexander M, Yang S, Yung R, **Brasic JR**, Pannu H. Diagnosis of benign solitary fibrous tumors by positron emission tomography. *South Med J*. 2004;97(12):1264-1267.
2. Alexander M, **Brašić JR**. The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET). *Clin Nucl Med*. 2006;31(9):566-567.
3. Alexander M, **Brašić JR**. 2-[¹⁸F]fluoro-2-deoxy-D-glucose ([¹⁸F]FDG) positron emission tomography (PET) for the diagnosis and treatment of Burkitt lymphoma. *J Biomed Graph Comput*. 2013;3(2):67-72.
4. Brasic JR. A 33-year-old woman with rigidity and stereotypies. Updated April 25, 2017. Available at: <http://reference.medscape.com/viewarticle/878930> Accessed on May 24, 2017.

Book Chapters, Monographs [BC]

1. Young JG, **Brasic JR**, Kisanadwala H, Leven L. Strategies for research on school refusal and related nonattendance at school. In: Chiland C, Young JG (with Kaplan D) (Editors). *Why children reject school: views from seven countries*. The Child in His Family, The Yearbook of the International Association for

Child and Adolescent Psychiatry and Allied Professions, Volume 10. Yale University Press, New Haven and London. 1990;199-223.

French edition: Young JG, **Brasic JR**, Kisanadwala H, Leven L: Stratégies pour la recherche sur le refus d'aller à l'école et la non-assiduité à l'école qui est liée aux États-Unis [Strategies for research on school refusal and school non-attendance in the United States]. In: Chiland C, Young JG (with Kaplan D) (Editors). Le refus de l'école: un aperçu transculturel [School refusal: a transcultural view]. Presses Universitaires de France, Paris, France. 1990;153-183.

2. Young JG, **Brasic JR**, Leven LI. Genetic causes of autism and the pervasive developmental disorders. In: Deutsch SI, Weizman A, Weizman R (Editors). Application of basic neuroscience to child psychiatry. Plenum Medical Book Company, New York. 1990;183-216.

3. Young JG, **Brasic JR**, Kaplan D, Golomb J, Ostrer H, Furman J, Biegon A. Advances in research techniques. In: Lewis M (Editor). Child and adolescent psychiatry: a comprehensive textbook. Williams & Wilkins, Baltimore. 1991;1201-1228.

Revised: Young JG, **Brasic JR**, Ostrer H, Kaplan D, Will M, John ER, Prichep L, Buchsbaum M. The developing brain and mind: advances in research techniques. In: Lewis M (Editor). Child and adolescent psychiatry: a comprehensive textbook, second edition. Williams & Wilkins, Baltimore. 1996;1209-1234.

4. **Brasic JR**, Young JG. Research design, measures, and statistics. In: Robson KS (Editor). Manual of clinical child and adolescent psychiatry, revised edition. American Psychiatric Press, Inc., Washington, DC. 1994;435-463.

5. Young JG, **Brasic JR**, Sheitman B, Studnick M. Brain mechanisms mediating aggression and violence. In: Chiland C, Young JG (with Kaplan D) (Editors). Children and violence. The Child in the Family, the Monograph Series of the International Association for Child and Adolescent Psychiatry and Allied Professions. Jason Aronson, Inc., Northvale, New Jersey, and London. 1994;13-48.

French first edition: Young JG, **Brasic JR**, Sheitman B, Studnick M. Mécanismes cérébraux médiateurs de l'agression et la violence [Cerebral mechanisms mediating aggression and violence]. In: Chiland C, Young JG (with Kaplan D) (Editors) (translated by Noizet Y). Les enfants et la violence [Children and violence] Monographies de l'Association internationale de Psychiatrie de l'enfant et de l'adolescent et des professions associées. Presses Universitaires de France, Paris, France. 1997;29-70.

French second edition: Young JG, **Brasic JR**, Sheitman B, Studnick M. Mécanismes cérébraux médiateurs de l'agression et la violence [Cerebral mechanisms mediating aggression and violence]. In: Chiland C, Young JG (with Kaplan D) (Editors) (translated by Noizet Y). Les enfants et la violence [Children and violence], second edition. Monographies de l'Association internationale de Psychiatrie de l'enfant et de l'adolescent et des professions associées. Presses Universitaires de France, Paris, France. 1998;29-70.

6. Young JG, Kaplan D, Pascualvaca DM, **Brasic JR**. Psychiatric examination of the infant, child, and adolescent. In: Kaplan HI, Sadock BJ (Editors). Comprehensive textbook of psychiatry/VI, sixth edition, Volume 2. Williams & Wilkins, Baltimore, Maryland. 1995;2169-2206.

7. Endres CJ, Dogan AS, **Brasic JR**, Zhou Y, Hilton J, London ED, Wong DF. Comparison between bolus

11

and infusion [¹¹C]raclopride delivery for the quantification of dopamine release. In: Senda M, Kimura Y, Herscovitch P (eds). Brain imaging using PET. Academic Press, Amsterdam. 2002;71-75.

8. Wong DF, Potter WZ, **Brasic JR**. Proof of concept: functional models for drug development in humans. In: Davis KL, Charney D, Coyle JT, Nemeroff C (editors). Neuropsychopharmacology: The Fifth Generation of Progress. The American College of Neuropsychopharmacology and Lippincott Williams & Wilkins, Baltimore, Maryland. 2002;457-473.

9. Zhou Y, Endres CJ, Dogan AS, **Brasic JR**, Wong DF, Huang S-C. A new linear parametric imaging algorithm derived from a simplified reference tissue model for ligand-receptor dynamic PET studies. In: Senda M, Kimura Y, Herscovitch P (eds). Brain imaging using PET. Academic Press, Amsterdam. 2002;33-39.

10. **Brašić JR**. Treatment of movement disorders in autism spectrum disorders. In: Hollander E (Editor). Autism Spectrum Disorders. Volume 24 of the Medical Psychiatry Series. ISBN 0-8247-0715-X Marcel

Dekker, Inc., New York. 2003;273-346.

11. Wong DF, Gründer G, Cascella NG, **Brašić JR**. Molecular brain imaging in schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P (Editors). Kaplan & Sadock's comprehensive textbook of psychiatry, ninth edition. Chapter 12.9 in Volume 1. Lippincott Williams & Wilkins, Philadelphia, 2009;1519-1530.

12. Wong DF, **Brašić JR**, Cascella N. Neuroreceptor imaging of schizophrenia. In: Shenton ME, Turetsky BI (Editors). Understanding neuropsychiatric disorders: insights from neuroimaging Cambridge University Press, Cambridge, UK, 2011;78-87.

13. **Brasic JR**, Mohamed M. Human brain imaging of autism spectrum disorders. In: Seeman P, Madras B (Editors). Imaging of the human brain in health and disease. Neuroscience-Net, LLC, 2012.

Revised edition: **Brasic JR**, Mohamed M. Human brain imaging of autism spectrum disorders. In: Seeman P, Madras B (Editors). Imaging of the human brain in health and disease. Academic Press, Elsevier Science, Oxford, UK, 2014;373-406.

14. George N, Gean E, Nandi A, **Brašić JR**, Wong DF. Radiotracers used to image the brains of patients with Alzheimer's disease In: Seeman P, Madras B (Editors). Imaging of the human brain in health and disease. Neuroscience-Net, LLC, 2012

Revised edition: George N, Gean E, Nandi A, **Brašić JR**, Wong DF. Radiotracers used to image the brains of patients with Alzheimer's disease In: Seeman P, Madras B (Editors). Imaging of the human brain in health and disease. Academic Press, Elsevier Science, Oxford, UK, 2014; 407-416.

15. Wong DF, Nandi A, Zaidi E, Gean E, Horti A, Frolov B, George N, **Brasic JR**. Brain PET imaging in the cannabinoid system. In: Seeman P, Madras B (Editors). Imaging of the human brain in health and disease. Neuroscience-Net, LLC, 2012.

Revised edition: Wong DF, Nandi A, Zaidi E, Gean E, Horti A, Frolov B, George N, **Brasic JR**. Brain PET imaging in the cannabinoid system. In: Seeman P, Madras B (Editors). Imaging of the human brain in health and disease. Academic Press, Elsevier Science, Oxford, UK, 2014;27-36.

16. Wong DF, **Brašić JR**, Gean E, Nandi A. The role of positron emission tomography (PET) in understanding addiction. In: MacKillop J, de Wit H (Editors). The Wiley-Blackwell handbook of addiction psychopharmacology. John Wiley & Sons, Chichester, UK, 2013;677-706.

17. **Brašić JR**, Kim J. The nicotine hypothesis. In: Madras B, Kuhar M (Editors). The effects of drug abuse on the human nervous system. Academic Press, Elsevier Science, Oxford, UK, 2014;313-332.

18. Wong DF, **Brašić JR**, Horti A, Gründer G. Molecular brain imaging in schizophrenia. In: Sadock BJ, Sadock VA, Ruiz P (Editors). Kaplan & Sadock's comprehensive textbook of psychiatry, tenth edition. Chapter 12.9 in Volume 1. Lippincott Williams & Wilkins, Philadelphia, 2017; 1488-1501.

Books, Textbooks [BK]

Other Publications: Suggested Additional Subcategory Titles: *May adjust as necessary for your specialty*

Proceedings Reports [PR]

Guidelines/Protocols, Consensus Statement, Expert Opinion, Consortium Articles [GL]

Editorials [ED]

Methods and Techniques, "How I Do It" articles [MT]

1. Smyth S, **Brasic JR**. Referee Report For: Vachon MJ, Striley CW, Gordon MR, Schroeder ML, Bihun EC, Koller JM, Black KJ. VISIT-TS: A multimedia tool for population studies on tic disorders [version 2; referees: 3 approved]. F1000Research 2016, **5**:1518 (doi: [10.5256/f1000research.10427.r16869](https://doi.org/10.5256/f1000research.10427.r16869)). [method article review]

Research Letters/White Papers/Brief Reports [RL]

Published Curricula [PC], Learner Assessment Tools, Educational Evaluations, Assessment/Evaluation Instruments [PC]

Letters, Correspondence [LT]

1. **Brasic JR**, Barnett JY, Sheitman BB, Tsaltas MO. Adverse effects of clomipramine. J Am Acad Child

Adolesc Psychiatry. 1997;36(9):1165-1166.

2. **Brašić JR**, Perry R. Unilateral auditory hallucinations in a boy with ipsilateral conductive hearing loss. J Neurol Neurosurg Psychiatry. 1997;62(3):302.

Revised: Brasic JR. A 9-year-old boy exhibiting violent behavior. Medscape. Updated May 31, 2016.

Available at: http://reference.medscape.com/viewarticle/863846_6 Accessed on June 7, 2016.

3. **Brašić JR**, Perry R. Unilateral auditory hallucinations: ear or brain? Brašić and Perry reply. J Neurol Neurosurg Psychiatry. 1997;63(6):814-815.

4. **Brašić JR**. Quinine-induced thrombocytopenia in a 64-year-old man who consumed tonic water to relieve nocturnal leg cramps. Mayo Clin Proc. 2001;76(8):863-864.

5. **Brašić JR**. Is stalking preventable? Med Hypotheses. 2005;64(4):878-879.

6. **Brašić JR**. Suicide is probably more common in untreated youths than in those receiving treatment: the need for a retrospective epidemiological study. Med Hypotheses. 2005;65(6):1204-1205.

Media Releases or Interviews [MR]

2. **Brašić JR**. How to speak well in public. Catalyst, Johns Hopkins Postdoctoral Association Newsletter. April, 2006;4:6.

3. **Brašić JR**. Asperger's syndrome: a guide for parents and professionals. By Tony Attwood. London: Jessica Kingsley Publishers, Ltd. 1998. Neurology. 1999;52:1112. [book review]

Other Media [OM] (Videos, Websites, Blogs, Social Media, etc.)

FUNDING (*in chronological order, earliest first by start date under each subcategory*)

For each grant or contract please provide the following information in this format:

Date	Title
	Identification number
	Sponsor
	Total direct cost
	Principal Investigator [<i>if not you</i>]
	Your role, your percent effort; Notes

EXTRAMURAL Funding (*Show as current, pending, previous under each subcategory and follow format above.*)

Research Extramural Funding - Grants or contracts obtained to support a research initiative

Current

12/15/14 -12/14/17 Positron Emission Tomography Imaging in Participants in the Baltimore Longitudinal Study of Aging

HHSN271201500005C

NIH/NIA – 119489

\$191,172

Wong

Co-investigator, 20% effort

Goal: Amyloid imaging on Baltimore Longitudinal Study of Aging subjects longitudinally (acquisition and collaboration on analysis)

08/05/15-07/31/18 (NCE) Imaging of alpha7-nAChR in Schizophrenia

R01 MH107197

NIH-120808

\$488,965

Wong

Co-investigator, 10% effort

Goal: To image alpha 7 nAChR with [18F]ASEM in healthy controls of patients with schizophrenia and to measure occupancy of single GTS-21/DXMB-A.

03/01/17-02/28/18 Alpha 7 nicotinic acetylcholine receptors as a potential pharmaceutical target for smoking cessation

Pfizer

\$149,236

Weerts

Co-investigator, 5 percent effort

Goal: The goal of this study is to develop biomarker to quantitatively measure alpha 1 nicotinic acetylcholine receptors in the brain of people with nicotine dependence to monitor the effectiveness of interventions.

07/01/14-02/28/18 Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Tau Imaging with Positron Emission Tomography in Healthy Control Subjects and Subjects with Alzheimer's Disease

BP29409

Roche

\$17,000

Wong

Co-investigator, 3% effort

Goal: This research involves use of investigational radioactive imaging agents (also called radiotracers or PET tracers) called [11C]RO6924963, [11C]RO6931643 and [18F]RO6958948. The use of [11C]RO6924963, [11C]RO6931643 and [18F]RO6958948 in this Study is for investigational purposes.

09/30/11-05/31/18 (NCE) Longitudinal imaging of neuropsychiatric symptoms in mild cognitive impairment

R01AG041633

NIA

\$1,662,417

Smith

Co-investigator, 20% effort

Goal: The project focuses on understanding the neurobiology of neuropsychiatric symptoms (NPS; depression, anxiety, irritability, agitation) and the relationship to cognitive decline in the early stages (mild cognitive impairment, MCI) to inform the development of disease-modifying treatments.

08/15/14-03/31/19 Biomarkers of Cognitive Decline Among Normal Individuals: The BIOCARD Cohort

U19 AG033655

NIH/NIA - 118133

\$1,962,918

Albert

Co-investigator, 11 percent effort

Goal: To identify biomarkers that predict progression from normal cognitive status to mild impairment or dementia.

04/01/17-03/31/19 Cannabinoid PET Imaging in Women Cannabis Users

R21DA043963

NIH, NIDA

\$150,000

Weerts

Co-investigator, 3 percent effort

Goal: The goal of this study is to develop biomarker to quantitatively measure cannabinoid Cb1 receptors in the brain of people with cannabis dependence to monitor the effectiveness of interventions during clinical trials.

07/10/14-04/30/19 Ethnic differences in endogenous pain regulation: PET imaging of opioid receptors

R01MD009063

NIH

\$250,000

Campbell

Co-Investigator, 5 percent effort

Goal: To investigate the endogenous opioid system as the mechanism underlying the disparities in pain sensitivity, thereby enhancing our understanding of the neurobiology of ethnic/racial differences in pain, which will assist in the refinement of targeted interventions to alleviate clinical pain in at-risk populations, and aid in reducing pain-related health disparities.

09/29/14-09/28/19 Early Markers of Alzheimer Disease: PET Tau Imaging in the Baltimore Longitudinal Study of Aging

HHSN271201400119C

NIH/NIA – 118546

\$198,986

Wong

Co-investigator, 9 percent effort

Goal: To assess the safety and efficacy of tau imaging in a longitudinal cohort of healthy adults.

08/10/15-06/30/20 Alcohol & Comorbid Tobacco Use Disorders: PET Imaging of Glutamate Effects

R01AA023483

NIH/NIAAA – 120848

\$416,301

Wong

Co-investigator, 10 percent effort

Goal: To study the effects of alcohol use disorder (AUD) and comorbid tobacco use disorder (TUD) on the glutamate neurotransmitter system.

04/01/17-03/31/22 Combined mGluR5 PET and fMRI imaging of Sex Differences during Cocaine Withdrawal

R01DA042094

NIH/NIDA

\$491,095

McCaul

Co-investigator, 5 percent effort

Goal: The goal of this study is to develop biomarker to quantitatively measure metabotropic glutamate type 5 receptors in the brain of men and women with cocaine dependence to monitor the effectiveness of interventions during clinical trials of cocaine withdrawal.

07/01/17-06/30/22 Molecular Imaging of STN DBS in Parkinson's Disease

NIH

\$499,533

Smith, Gwenn

Co-investigator, 10 percent effort

Goal: The goal of this study is to quantitatively measure neurotransmission in people with Parkinson's disease during the course of treatment with deep brain stimulation (DBS) in the subthalamic nucleus (STN).

Pending

09/01/17-08/31/22 Neural Basis of Individual Differences in Motivation and Cognitive Control

NIH

\$420,124

Courtney-Faruqee

Co-investigator, 1 percent effort

Goal: The goal of this study is to quantitatively measure dopamine D2 receptors in the brain of people during continuous performance tasks of varying degrees of motivation.

04/01/2018-03/31/2020 Glutamate Receptor Function in Fragile X Syndrome

NIH

\$275,000

Principal Investigator, 17% effort

Goal: To quantitatively measure the density and the distribution of metabotropic glutamate receptors, subtype 5 (mGluR₅) in men with fragile X syndrome

07/01/2018-06/30/2020 Metabotropic glutamate receptor 5 function in autism spectrum disorder (ASD)

Simons Foundation for Autism Research Initiative (SFARI)

\$330,000

Principal Investigator, 17% effort

Goal: To quantitatively measure the density and the distribution of metabotropic glutamate receptors, subtype 5 (mGluR₅) and signs and symptoms of autism spectrum disorder (ASD) in men with ASD and typical men.

Previous

07/01/00-06/30/02 Dysfunction of high-affinity alpha 4/beta 2 nicotinic acetylcholine neuronal receptors in schizophrenia

M630-678-2264

Brain and Behavior Research Foundation NARSAD Young Investigator

Grants, 2000

Named an Essel Investigator funded by the Essel Foundation.

\$60,000.00

Principal Investigator, 7 percent effort

Goal: This application proposes to investigate the density and the distribution of alpha 4/beta 2* nicotinic acetylcholine neuronal receptors in people with schizophrenia.

07/01/02-06/30/04 Dysfunction of high-affinity alpha 4/beta 2 nicotinic acetylcholine neuronal receptors in schizophrenia

M630-678-2308

Brain and Behavior Research Foundation NARSAD Young Investigator

Grants, 2002

Named an Essel Investigator funded by the Essel Foundation

\$60,000.00

Principal Investigator, 7 percent effort

Goal: This application proposes to investigate the density and the distribution of alpha 4/beta 2* nicotinic acetylcholine neuronal receptors in people with schizophrenia.

09/05/06-06/30/14 Mechanisms in Dopamine and Serotonin in Tourette Syndrome

R01 MH078175

NIH/NIMH

\$?

Wong

Co-investigator, ? percent effort

Goal: To examine the normal physiological regulation of the dopaminergic (DA) and serotonergic (5-HT) systems and to evaluate dysfunction of these systems in Tourette Syndrome (TS).

08/01/09-07/31/14 Development of PET Radioligands for Cerebral Cannabinoid Receptor (CB1)

R33 MH079017

NIH/NIMH

\$?

Horti

Co-investigator, ? percent effort

Goal: To develop a radioligand for quantitative positron emission tomography (PET) imaging of the cerebral cannabinoid receptor (CB1) in human subjects.

03/15/11-02/29/16 Cortical and Subcortical Mechanisms of Human Cognitive Control

R01 DA013165

NIH/NIDA-109890

\$404,905

Courtney-Faruqee

Co-investigator, 10 percent effort

Goal: Measuring fMRI and dopamine during attentional task.

09/30/11-05/31/16 Longitudinal imaging of neuropsychiatric symptoms in mild cognitive impairment
R01 AG041633
NIH/ NIA -111215
\$357,724
Smith G
Co-investigator, 20 percent effort

Goal: To assess longitudinal imaging of neuropsychiatric symptoms in subjects with mild cognitive impairment.

03/01/13-02/28/15 Geriatric Depression: PET Studies of Pathophysiology and Treatment Response
R01 1MH086881
NIH/NIMH
\$?
Co-investigator, ?percent effort

Goal: To provide unique data regarding beta-amyloid deposition and serotonin transporter binding in Alzheimer's disease as substrates for cognitive and affective symptoms in Alzheimer's disease.

10/24/14-10/23/15 An Open-Label Positron Emission Tomography (PET) Study to Demonstrate Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of ITI-007 in Stable Schizophrenia Patients
ITI-007-008
IntraCellular Therapies Inc.

\$?

Wong
Co-investigator, ? percent effort

Goal: To demonstrate receptor occupancy, safety, tolerability and pharmacokinetics of ITI-007 in stable patients with schizophrenia.

08/01/14-11/30/15 In Vivo Measurement of Metabotropic Glutamate Receptor 5 in Brains of Subjects
N004476401
University of Minnesota
\$?
Wong
Co-investigator, ?percent effort

Goal: To study in vivo measurement of metabotropic glutamate Receptor 5 in brains of subjects with autism.

07/01/14-04/30/16 Ethnic differences in endogenous pain regulation: PET imaging of opioid receptors
R01MD009063
NCMHD – 117715
\$250,000
Campbell
Co-investigator, 5 percent effort

Goal: To investigate the endogenous opioid system as the mechanism underlying the disparities in pain sensitivity, thereby enhancing our understanding of the neurobiology of ethnic/racial differences in pain, which will assist in the refinement of targeted interventions to alleviate clinical pain in at-risk populations, and aid in reducing pain-related health disparities

07/01/14-06/30/16 Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as tracers for tau imaging with positron emission tomography in healthy control subjects and subjects with Alzheimer's disease

BP29409

ROCHE TCRC Inc

\$?

Wong

Co-investigator, ?percent effort

Goal: To assess the safety and efficacy of potential tracers for tau imaging in healthy people and people with Alzheimer's disease.

09/01/11-08/31/16 PET Studies of Serotonin and Amyloid in MCI

R01 AG038893

NIH/NIA

\$?

Smith,G

Co-Investigator, ? percent effort

Goal: The studies will use PET to evaluate the relationship between amyloid deposition and serotonin transporter availability in MCI.

12/15/14-12/14/16 Positron Emission Tomography Imaging in Participants in the Baltimore Longitudinal Study of Aging

HHSN271201500005C

NIH/NIA – 119489

\$186,989

Wong

Co-investigator, 20 percent effort

Goal: Amyloid imaging on BLSA subjects longitudinally (acquisition and collaboration on analysis).

08/01/12-07/31/17 Amyloid Neuroimaging in Older HIV+ Individuals with Cognitive Impairment

R01NS081196

NIH/NINCDS-113418

\$474,904

Sacktor

Co-Investigator, 5 percent effort

Goal: This proposal will use a novel PET measure likely available for clinical use in 2012, to determine whether abnormal amyloid deposition is present in the brain at a chronologically inappropriate age in HIV+ individuals and whether it is associated with cognitive impairment, and executive functioning decline.

08/05/15-07/31/17 Imaging of alpha7-nAChR in Schizophrenia

R01 MH107197

NIH-120808

\$507,149

Wong

Co-investigator, 31 percent effort

Goal: To image alpha 7 nAChR with [18F]ASEM in healthy controls of patients with schizophrenia. Also to measure occupancy of single GTS-21/DXMB-A.

12/15/14 -12/14/17 Positron Emission Tomography Imaging in Participants in the Baltimore Longitudinal Study of Aging

HHSN271201500005C

NIH/NIA – 119489

\$191,172

Wong

Co-investigator, 20 percent effort

Goal: Amyloid imaging on BLSA subjects longitudinally (acquisition and collaboration on analysis).

Educational Extramural Funding – Grants or contracts obtained to support an educational initiative, incl. training grants

Clinical Extramural Funding - Grants or contracts obtained to support a clinical initiative

System Innovation or Quality Improvement Extramural Funding - Grants or contracts obtained to support an initiative

Other Extramural Funding, including philanthropy

INTRAMURAL Funding (*Show as current, pending, previous under each subcategory and follow format above.*)

Research Intramural Funding

Current

08/01/16-07/31/18 Preliminary study of instrumentation to quantitatively measure movement disorders

IRB00110166

None

None

Principal Investigator, 0% effort

Goal: To: (1) test the feasibility of an accelerometry-based device to acquire motion data of patients with a variety of movement disorders and healthy matched controls, and (2) to begin to develop signal processing algorithms that can objectively and reliably analyze the collected data to identify pathognomonic motor patterns of patients' conditions, and that can be used to further objectify and more accurately quantify movement disorder ratings scales like the MDS-UPDRS.

Pending

03/01/18-02/28/19 Feasibility of an *in vivo* investigation of coregistration of quantitative movement measurement and magnetic resonance imaging in the living human brain of people with Parkinson disease

Gatewood Award, Johns Hopkins University

\$20,000

Brasic

PI

Goal: The goal of this study is to differentiate correlation of quantitative measurements of movements in upper and lower extremities with resting state functional magnetic resonance imaging in participants with Parkinson's disease and matched controls.

In preparation

Feasibility study of dopamine release normalization in Tourette syndrome treated with an oral orthotic appliance

Principal Investigator, 0% effort

Goal: This pilot study will utilize positron emission tomography (PET), a highly sensitive imaging procedure, to uniquely provide novel parameters to characterize dopamine release in a subset of people with Tourette syndrome with frequent oral tics before and after the administration of an oral orthotic appliance and matched healthy control participants. The aim of this study is to develop a biomarker tool to characterize the pathophysiology of the dopaminergic axis in unmedicated people with Tourette syndrome

before and after treatment with an oral orthotic appliance and matched healthy adults. This innovation will provide a sound basis to understand the metabolic abnormalities of a subset of individuals with Tourette syndrome of to facilitate the quantitative measurement of relevant parameters for oral orthotic appliances and other therapeutic applications.

Feasibility of an *in vivo* investigation of dopamine neurotransmission and movement correlation in people with Parkinson's disease who undergo deep brain stimulation
Principal Investigator, 0% effort

Goal: This pilot study will utilize positron emission tomography (PET), a highly sensitive imaging procedure, to uniquely provide novel parameters to characterize dopamine transporter and movements in a subset of people with Parkinson disease who have undergone deep brain stimulation. The aim of this study is to develop a nuclear biomarker tool and a movement technology to characterize the pathophysiology of the dopaminergic axis in people with Parkinson disease who have undergone deep brain stimulation and matched healthy adults.

In preparation

Proof of concept of striatal dopaminergic function in Cornelia de Lange syndrome
Cornelia de Lange Syndrome Foundation
\$15,000
Principal Investigator, 0% effort

Goal: This pilot study will utilize positron emission tomography (PET), a highly sensitive imaging procedure, to uniquely provide novel parameters to characterize dopamine in individuals with Cornelia de Lange syndrome (CdLS). The aim of this study is to test the hypothesis that in contrast to healthy individuals without CdLS, individuals with CdLS exhibit the association of reduced striatal dopamine neurotransmission along with self-injury, reduced attention, increased anxiety, increased stereotypies, and other autistic traits.

Educational Intramural Funding
Clinical Intramural Funding
System Innovation or Quality Improvement Intramural Funding
Other Intramural Funding

Overlap: No scientific or budgetary overlap

Should awards be made that increase active support to over 100%, existing budgets will be reduced appropriately.

CLINICAL ACTIVITIES

Clinical Focus

Diagnosis and assessment of neuropsychiatric disorders

- A children's global assessment scale (CGAS) [OR 1] [BC 10]
- Autism Screening Checklist (Brasic, 2014) [RA 31]
- Demographic Coding Form (DCF) [RA 16]
- Discharge Planning Quality Rating Survey (DPQRS) [OR 18] [BC 10]
- Family Compliance Checklist (FCC) [OR 9] [BC 10]
- Global Self-Injurious Behavior Scale (GSIBS) [BC 10]
- Movement Disorders Checklist (MCC) [BC 10]
- Myoclonus Versus Tic Checklist (MVTC) [RA 9] [BC 10]

- Psychoactive Medication Quality Assurance Rating Survey (PQRS) [OR 6] [BC 10]
- Psychoactive Medication Quality Assurance Rating Survey (PQRS) Screening Criteria [OR 21]
- Timed Self-Injurious Behavior Scale (TSIBS) [OR 7] [BC 10]
- Timed Stereotypies Rating Scale (TSRS) [OR 21]

Certification

Medical, other state/government licensure

Date	State info, identification #, any explanatory notes
Current	
12/5/1973	California, G 026119
12/8/1998	Maryland, D0054227
7/31/2001	Maryland Controlled Dangerous Substances, M49807
7/24/2013	Maryland Controlled Dangerous Substances Research, R65111 Drug Enforcement Administration confidential data available on request
2/15/1980	New York, 141218
Expired	
11/25/1988 – 2/28/1989	Connecticut, 029587
5/22/1975 – 7/31/1999	Illinois, 036-050991

Boards, other specialty certification

Date	Specialty name, identification #, any explanatory notes
7/2/1973	National Board of Medical Examiners 126004
	American Board of Psychiatry and Neurology, Inc.
6/30/1982	recertified 10/28/2013 Neurology 23742
6/30/1984	Psychiatry 26028
9/30/1988	Child and Adolescent Psychiatry 2286

Clinical (Service) Responsibilities

Date	Role/time commitment, specialty
Outpatient	Two neuropsychiatric evaluations per week
Inpatient	One hospitalization on the Clinical Research Unit per month

Clinical Productivity (such as the annual number of patients evaluated or treated, procedures performed, tertiary referrals, wRVUs, etc.)

100 patients evaluated per year
200 positron emission tomography scans per year

Clinical Draw from outside local/regional area (reflecting national/international reputation)

Date
Participants from throughout North America

Membership in or examiner for specialty board

Date Role; name of specialty board
6/30/1982 American Board of Psychiatry and Neurology, Inc. Maintenance of certification in Neurology

Clinical Program Building / Leadership

Date Role/percent effort; name of clinical program; impact of program outside of JHMI/region
None

Clinical Demonstration Activities to external audience, on or off campus

Date Clinical technique/procedure/program, observing party, venue

None

Development of nationally/internationally recognized clinical standard of care (*may not be published in peer-reviewed journals*):

Date

None

EDUCATIONAL ACTIVITIES (*in chronological order, earliest first by start date under each subcategory*)

Educational Focus (*Optional--provide up to 100 word narrative, bulleted accomplishments, or key words that express your educational focus*)

One-to-one instruction in the design, conduct, and analysis of clinical research

Teaching (*Include date, role, learner level, course title, venue; please separate JHMI/Regional from National and International activities*)

Classroom instruction

Date Role, learner level, course title, venue; any explanatory notes

2014 – Instructor, Medical Student IV, Radiology Elective (Course Director: Dr. Donna Magid), Johns Hopkins Hospital, one hour lecture to teach students nuclear neuroimaging

Clinical instruction

Date Role, learner level, course title, venue; any explanatory notes

2014 – Preceptor, Medical Student II, Transition to the wards, Johns Hopkins Hospital, two hours per week for three weeks to teach students to interview and examine inpatients

CME instruction

Date Role, learner level, course title, venue; any explanatory notes

JHMI/Regional

National

International

None

Workshops /seminars

Date Role, learner level, course title, venue; notes

JHMI

2014 Instructor, Radiology assistant professors, instructors, and research associates in peer-to-peer mentoring program, Johns Hopkins Hospital, “Publication for promotion”

2015 Instructor, Johns Hopkins Medicine Postdoctoral Association Research Presentations Club, Johns Hopkins Hospital, “Optimal scientific presentations”

2016 Instructor, Community including people at Johns Hopkins University, “How to listen effectively” from the Success/Communication Program of Toastmasters International for three hours, Johns Hopkins Hospital

2017 Instructor, Johns Hopkins Medicine Postdoctoral Association Research Presentations Club, Johns Hopkins Hospital, “How to deliver optimal oral scientific speeches”

2017 Presenter of lightning pitch entitled “Quantitative continuous measurement of resting state functional magnetic resonance imaging and movements in people with Parkinson's disease” at the Johns Hopkins Research Symposium on Engineering in Healthcare, Johns Hopkins University, Baltimore, Maryland, November 20, 2017

JHMI/Regional

National

International

Mentoring (*Please list only mentees who have received substantive and sustained mentoring in clinical, research, and/or educational activities.*)

Pre-doctoral Advisees /Mentees

Date	Mentee name, degree, present position; awards/grants/degrees received under your direction, indicate shared publications scholarship by numbered entries in this CV
6/27/2016-8/19/2016	Gregory McKay, BA, BS, Medical Student 1, summer research rotation in MD-PhD Program
1/01/2017-present	Brian Hwang, neuroscience undergraduate, research elective [RA 36]

Post-doctoral Advisees /Mentees

Date	Mentee name, degree, present position; awards/grants/ degrees received under your direction, indicate shared publications scholarship by numbered entries in this CV
2004-2006	Mohab Alexander, MD, Hospital and Health Care Professional, Phoenix, Area, two grants from the loan repayment program of NIH to examine differential effects of stimulants [OR 24, 27, 28, 29, 31, 33, 34, 35, 36, 37] [CR 1,2,3]

Thesis committees

Date	Mentee name, thesis title (if available), your role, any explanatory notes
None	

Educational Program Building / Leadership

Date	Role/percent effort, name of educational program or curriculum, any explanatory notes
------	---

Toastmasters International®

Awards from Toastmasters International®

08/01/2004	Competent Toastmaster
01/01/2005	Old Competent Leader
02/01/2005	Advanced Toastmaster Bronze
08/01/2005	Advanced Toastmaster Silver
05/16/2007	Advanced Communicator Gold
03/07/2008	Competent Communicator
05/15/2008	Advanced Communicator Bronze
01/21/2010	Advanced Communicator Silver
08/01/2011	Competent Leader
05/03/2012	Leadership Excellence
10/08/2014	Advanced Leader Silver
11/26/2104	Distinguished Toastmaster
02/02/2016	Advanced Communicator Gold
05/06/2016	Competent Communicator
06/30/2016	
	Advanced Leader Bronze
10/17/2016	Competent Leader
11/10/2016	
	Advanced Leader Bronze
12/13/2016	Advanced Communicator Bronze

District 18

07/01/2011-06/30/2012 Area Governor

Hopkins Toastmasters Club, Johns Hopkins Hospital, Baltimore, Maryland
2.5 hours monthly

07/01/2004-06/30/2006 Vice President Membership

07/01/2005-06/30/2006 Sargeant at Arms

07/01/2006-06/30/2008 President

07/01/2008-06/30/2012 Vice President Education

Electronic medical record

Epic

Superuser

Support for launch

2014 Suburban Hospital, Bethesda, Maryland

2015 Emergency Department, Johns Hopkins Hospital, Baltimore, Maryland

2016 Johns Hopkins Hospital, Baltimore, Maryland

Educational Demonstration Activities to external audiences, on or off campus

Date Educational technique or program, observing party, venue

RESEARCH ACTIVITIES (*in chronological order, earliest first by start date under each subcategory*)

Research Focus (*Optional--provide up to 100 word narrative, bulleted accomplishments, or key words that express your research focus; or include NIH Biosketch section A here*)

I have a broad background in medicine, with specific training and expertise in neurology and child and adolescent psychiatry as well as positron emission tomography of neuropsychiatric disorders. My research includes neurotransmitter changes associated with developmental disabilities. As PI or co-Investigator on several previous funded grants, I laid the groundwork for research by conducting PET for healthy adult volunteers and adults with psychiatric disorders to estimate the density and the distribution of mGluR5s in the living human brain. I successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers, and produced several peer-reviewed publications from each project. As a result of these previous experiences, I am aware of the importance of frequent communication among project members and of constructing a realistic research plan, timeline, and budget.

Research Program Building / Leadership

Date Role, name of research / basic science program, notes

None

Research Demonstration Activities to external audience, on or off campus

Date Research technique, observing party, venue

None

Inventions, Patents, Copyrights (note pending or date awarded)

Date Filed Role, title, any explanatory notes, date awarded

7/26/2016 Disclosure executed, Inventor with Timothy Harrigan and Gregory McKay, Correlation of quantitative measurement of movements and positron emission tomography, pending

Technology Transfer Activities (e.g. Company Start-ups)

Date Role, title, notes

None

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES (*in chronological order, earliest first by start date under each subcategory. Indicate None or Not Applicable if no information is available for this section and delete the subcategories. Do not duplicate activities already shown above.*)

None

System Innovation Focus (*Optional--provide up to 100 word narrative, bulleted accomplishments, or key words that express your SI/QI focus*)

System Innovation and Quality Improvement efforts within JHMI:

Date Role/percent effort; name of site intervention, venue (s), and results (e.g., clinical outcomes, process measures, financial)

System Innovation and Quality Improvement efforts outside of JHMI:

Date Role/percent effort; name of site intervention, venue(s) and results (e.g., clinical outcomes, process measures, financial)

System Innovation and Quality Improvement Program Building/Leadership:

Date Role/percent effort; name of Innovation and QI program

ORGANIZATIONAL ACTIVITIES (*in chronological order, earliest first by start date under each subcategory*)

Institutional Administrative Appointments

Date Role, Committees, any explanatory notes

None

Editorial Activities

Editorial Activities

With Dean Wong, MD, PhD, and Gerhard Gründer, MD, editor of book entitled *Imaging for Neuropsychiatric Illness* to be published by World Scientific Publishing, Singapore

Editorial Board appointments

Date Role, Editorial Board name

1999 -- Peer Review Board of the Editorial Board of The WWW Journal of Online Education (JOE) for the World Association for Online Education 1999-present
<http://www.nyu.edu/classes/keefer/waoe/waoej.html>

Journal peer review activities

Date Journal full name (*do not abbreviate here*)

1991 Reviewer for the AOTA Self Study Series: Neuroscience Foundations of Human Performance. Rockville, Maryland: The American Occupational Therapy Association, Inc.

1998 -- Reviewer for Psychological Reports

1999 -- Reviewer for Perceptual and Motor Skills

2000 Reviewer for the North American Journal of Psychology

2000 Reviewer for The Journal of Critical Illness

2004 Reviewer for Social Science and Medicine

2007 -- 2008 Reviewer for Food Additives and Contaminants

2007. Reviewer for Expert Review of Dermatology

2009 --	Reviewer for Irish Journal of Medical Science
2008 --	Reviewer for CNS Spectrums
2012	Reviewer for CNS & Neurological Disorders-Drug Targets
2012 --	Reviewer for Journal of Psychiatry and Neuroscience
2012 --	Reviewer for Molecular Imaging & Biology
2012	Reviewer for The International Journal of Neuropsychopharmacology
2013	Reviewer for The Journal of Neurochemistry
2013	Reviewer for Journal of Photochemistry and Photobiology A: Chemistry
2015	Reviewer for HSOA Journal of Addiction and Neuropharmacology
2015	Reviewer for Comprehensive Psychology
2015	Reviewer for PLOS One
2015	Reviewer for Movement Disorders
2015 --	Reviewer for British Journal of Psychiatry
2016-	Reviewer for F1000Research
2016-	Reviewer for JAMA

Other peer review activities [*non medico-legal*]

Date	Role, sponsor/group
2014 --	Participant, Department of Mental Health and Substance Abuse of The World Health Organization, Geneva, Switzerland, Internet-Based Field Study for ICD-11 Mental and Behavioural Disorders

Advisory Committees, Review Groups/Study Sections

Date	Role, sponsor/organization/group
2006 -- 2008	External Reviewer for grant application, Canadian Institutes of Health Research Instituts de recherche en santé du Canada
2012	Reviewer for Clinical Research Unit of the Johns Hopkins University School of Medicine, Baltimore, Maryland
2016	Reviewer for South African Medical Research Council (MRC) for grant application, Cape Town, South Africa

Professional Societies

Date-	Society, Role, committee
1980 --	American Academy of Child and Adolescent Psychiatry, Fellow
1973 --	American Academy of Neurology, General Member
1995 --	Movement Disorder Society, Member
2008 --	Society for Nuclear Medicine and Molecular Imaging, Member
2017 --	Society for Neuroscience, Member

Conference Organizer (*separate into JHMI/Regional - National - International activities*)

Date	Sponsor/organization/group
------	----------------------------

Session Chair (*separate into JHMI/Regional – National - International activities*)

Date	Sponsor/organization/group
11/12/2017	Parkinson's disease: human therapeutic studies. Program No. 189.00. 2017 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2017.

Consultantships

Date	Organization/agency, notes
2001 --	Member, Medical Advisory Board of the Tourette Syndrome Association, Inc., Mid-Atlantic Chapter, Pikesville, Maryland

RECOGNITION *(in chronological order, earliest first by start date under each subcategory)*

Awards, Honors

Date	Title, description, sponsor, any explanatory notes
1966 -- 1972	Boston University Honors Accelerated Six-Year Program in Liberal Arts and Medical Education
1966 -- 1972	Boston University College of Arts and Sciences, Dean's Honor List, A. B. cum laude
1979	Air Force Commendation Medal, United States Air Force
1979	Faculty Recognition Award, Department of Psychiatry, Wright State University School of Medicine
1988	Fellowship, American Academy of Child and Adolescent Psychiatry
1990	Who's Who in the East, 23rd Ed. 1991-92. Wilmette, Illinois: Marquis Who's Who, 1990, page 94.
1992	Who's Who of Emerging Leaders in America, 4th Ed., 1993-1994. Marquis Who's Who, New Providence, New Jersey, page 129.
1996	Who's Who in Medicine and Healthcare, 1st Ed., 1997-1998. New Providence, New Jersey: Marquis, page 125.
2002 -- 2003	Guide to America's Top Psychiatrists, 2002-2003 Edition Washington, DC: Consumers' Research Council of America www.consumersresearchcncl.org
2004 -- 2005	Guide to America's Top Psychiatrists, 2004-2005 Edition, Second Edition Washington, DC: Consumers' Research Council of America www.consumersresearchcncl.org
2004 -- 2005	Guide to America's Top Physicians, 2004-2005 Edition, Second Edition Washington, DC: Consumers' Research Council of America www.consumersresearchcncl.org
2006	Who's Who in Science and Engineering®, 9 th Edition, 2006-2007. New Providence, New Jersey. Marquis. www.marquiswhoswho.com
2006	Guide to America's Top Physicians, 2006 Edition. Washington, DC: Consumers' Research Council of America www.consumersresearchcncl.org
2007	Guide to America's Top Psychiatrists, 2007 Edition, Washington, DC: Consumers' Research Council of America www.consumersresearchcncl.org
2007	Who's Who in Science and Engineering®, 2008-2009, 10 th Edition. Marquis Who's Who, New Providence, New Jersey, page 202. www.marquiswhoswho.com
2007	Brasic JR , Singer HS, Kumar A, Kuwabara H, Ye W, Alexander M, Maris MA, Nandi A, Gjedde AH, Grace AA, Wong DF. Correlations of dopamine release and neuropsychiatric symptoms in Tourette's syndrome presented at the Neurosciences Young Investigator Award Symposium of the Society of Nuclear Medicine 54th Annual Meeting at the DC Convention Center, in Washington, DC, June 2-6, 2007
2008	Brasic JR , Singer HS, Kumar A, Kuwabara H, Zhou Y, Ye W, Alexander M, Gelecki J, Gjedde AH, Grace AA, Wong DF. Correlation of the release of dopamine and psychiatric symptoms in Tourette's syndrome presented at the Brain Imaging Council Young Investigator Award Symposium of the Society of Nuclear Medicine 55th Annual Meeting at the Ernest N. Morial Convention Center, New Orleans, Louisiana, June 14-18, 2008
2009	Guide to America's Top Physicians, 2009 Edition. Washington, DC: Consumers' Research Council of America www.consumersresearchcncl.org
2009	Who's Who in America®, 2010, 64 th Edition. Marquis Who's Who, New Providence, New Jersey, www.marquiswhoswho.com
2010	Guide to America's Top Physicians, 2010 Edition. Washington, DC: Consumers' Research Council of America www.consumersresearchcncl.org
2011	Guide to America's Top Physicians, 2011 Edition. Washington, DC: Consumers' Research Council of America www.consumersresearchcncl.org
2012	Leader Excellence Award for High Performance Leadership Program. Toastmasters International, Buena Vista, California.

- 2012 Who'sWho in America®, 2013, 67th Edition. Marquis Who'sWho, New Providence, New Jersey, www.marquiswhoswho.com
- 2012 Guide to America's Top Physicians, 9th Edition, Washington, DC: Consumers' Research Council of America www.consumersresearchcncl.org
- 2013 Guide to America's Top Physicians, 10th Edition, Washington, DC: Consumers' Research Council of America www.consumersresearchcncl.org
- 2013 Who'sWho in America®, 2014, 68th Edition. Marquis Who'sWho, Berkeley Heights, New Jersey, www.marquiswhoswho.com
- 2014 America's Top Physicians. SLD Industries, Valencia, CA
- 2014 Who'sWho in America®, 2015, 69th Edition. Marquis Who'sWho, New Providence, New Jersey, www.marquiswhoswho.com
- 2015 **Brasic JR**, Sedlak TW, Mathur A, Dogan AS, Nandi A, Mellinger-Pilgrim RA, Kitzmiller KA, Gruender GM, Gjedde AH, Wong DF. A preliminary report of an in vivo investigation of amphetamine-induced dopamine release in schizophrenia, Top Poster Award Candidate, Neuroscience Track, 62nd Annual Meeting, Society of Nuclear Medicine and Molecular Imaging, Convention Center, Baltimore, Maryland, June 6-10, 2015
- 2015 Who'sWho in America®, 2016, in press, 70th Edition. Marquis Who'sWho, New Providence, New Jersey, www.marquiswhoswho.com,

Invited Talks (such as grand rounds, keynote addresses, visiting professorships. *Do not duplicate entries already shown above.*)

Date Title, sponsor, venue, any explanatory notes

JHMI/Regional

National

4/21/2016 Nuclear neuroimaging, West Virginia University, Ambulatory positron emission tomography (AMPET) workshop, GE Global Research Center, Niskayuna, New York

International

OTHER PROFESSIONAL ACCOMPLISHMENTS (*Optional*)

Posters

Oral/Podium Presentations [abstracts that were both presented orally and published]

17th Annual Meeting of the Vision Sciences Society in St. Pete Beach, Florida, on May 19-24, 2017
 Brian Anderson, Hiroto Kuwabara, Dean Wong, Joshua Roberts, Arman Rahmim, James Brašić, Susan Courtney; Learning mechanisms underlying value-driven attention. *Journal of Vision* 2017;17(10):1101. doi: 10.1167/17.10.1101. [abstract]

[Authors]. [Abstract Title]. Program No. XXX.XX. 2017 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2017. Online.

Harrigan T, **Brasic JR**, McKay GN, Mills KA, Hwang BJ, Mishra C, Pantelyat A, Fayad L, Wong DF. Accelerometry in Parkinson's disease. Program No. 189.08. 2017 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2017. Online.
<http://www.abstractsonline.com/pp8/#!/4376/presentation/34603> [abstract]

Hwang BJ, McKay GN, Harrigan T, C. Mishra C, Pantelyat A, Wong DF, **Brasic JR**. Test-retest of instrumentation to quantitatively measure movements of Parkinson's disease. Program No. 189.09. 2017 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2017. Online.
<http://www.abstractsonline.com/pp8/#!/4376/presentation/34604> [abstract]

Brasic JR, McKay GN, Hwang BJ, Harrigan TP, Mishra C, Mills KA, Pantelyat A, Bang J, Rosenthal L, Mathur A, Kitzmiller K, Wong DF. Quantitative continuous measurement of movements in the extremities of people with Parkinson's disease. Program No. 189.10. 2017 Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 2017. Online.
<http://www.abstractsonline.com/pp8/#!/4376/presentation/34605> [abstract]

[Military Service](#)

1972 -- 1979 United States Air Force Reserve Medical Corps, Second Lieutenant to Major

[Community Services](#)

[Humanitarian Activities](#)

[Philanthropic Activities](#)

[Other](#)

Press interview

1. Swingle AB. Orators in the making. Dome, a publication for all the members of the Johns Hopkins Medicine family. November, 2006; 57 (9): 6. Available at:

http://www.hopkinsmedicine.org/dome/0611/service_excellence2.cfm on August 8, 2014.

2. Hamberger D. Gulp! How to survive public speaking and live to tell about it. Gazette, Johns Hopkins University's bimonthly news magazine. March-April 2014; 43; 54. Posted in University News, Gazette, Johns Hopkins University, Baltimore, Maryland. Available at: <http://hub.jhu.edu/gazette/2014/march-april/personal-story-toastmasters> on August 8, 2014.

Television appearances

1. **Brasic JR.** Autistic disorder and intentional aggression. (J. Phillips, Interviewer). News. (1994, December 19, at 10 pm, and 1994, December 20, at 1 am). New York, New York: WPIX channel 11.